ArticleInvestigative ophthalmology & visual science2025
Calcitonin Gene-Related Peptide Ameliorates Experimental Dry Eye Disease.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune inflammatory targets and anti-inflammatory therapy in dry eye disease.International ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Calcitonin gene-related peptide (CGRP) level is reduced in the tears of patients with dry eye disease (DED). The current study aims to investigate the expression and therapeutic potential of CGRP as topical eye drops in treating experimental DED. Methods: Human corneal epithelial cells (CECs) were cultured under hyperosmotic stress (HS) and the effects of CGRP on cell viability, proliferation, migration, and apoptosis were determined in vitro. The expression of CGRP in the cornea and trigeminal ganglion (TG) of desiccating stress-induced experimental DED mice was determined. CGRP or albumin control were topically applied thrice daily for two weeks in DED mice and DED parameters were assessed clinically. Cornea and conjunctiva were collected separately after treatment, and cell proliferation and tissue inflammation were determined using immunostaining and flow cytometry. Results: Experimental DED mice showed significantly reduced CGRP mRNA and protein expression in their cornea and TG. CGRP promoted proliferation and downregulated apoptosis, TNF-α, IL-1β, and IL-6 mRNA levels during HS in cultured CECs. Clinically, topical application of CGRP significantly decreased corneal fluorescein staining score, increased tear break-up time, and preserved corneal epithelium in DED mice. In the cornea, CGRP significantly promoted epithelial proliferation and reduced infiltrating CD45+ leukocytes, and TNF-α and IL-1β expression in vivo. CGRP treatment did not significantly affect the frequency of CD45+ leukocytes in the conjunctiva. Conclusions: Our data demonstrate that CGRP expression in the cornea and TG is downregulated in DED. Topical CGRP treatment ameliorates DED severity by promoting epithelial proliferation and suppressing inflammation in the cornea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.